NMT introduced Nometex™, a new transdermal neuromodulation device to treat patients with chemotherapy-induced nausea and vomiting (CINV), at the 2011 scientific meeting of the American Society of Clinical Oncology (ASCO).

Leading Neuroscience company wins first place in the Later Stage Company category for its cutting-edge transdermal neuromodulation theruapeutic technology.

NMT is one of twelve finalist competing for a chance to named one of Illinois’s most innovative companies. NMT was selected from over 90 companies, and will present during the final competition on December 16, 2010 in Chicago, IL.

NMT announced an expanded focus of its core direction and key executive biographies.

NMT announced the release of an innovative new device for the treatment of post-operative nausea, medically referred to as emesis.

It has come to our attention that a component used in the manufacture of certain lots of our OTC device for motion sickness may not function properly. This problem impacts only the specified lots of the Explorer, model RB-EL, which are listed below.

NMT completed the acquisition of all global rights, corporate assets, technology, trademarks, and intellectual property of Woodside Biomedical, Inc.

NMT reinstated the production and distribution of the ReliefBand® Medical Device in September 2008.

Although no significant differences occurred on the first day of chemotherapy or in overall quality of life scores, significant differences in nausea/vomiting did occur for the overall five-day period. The group with the active Reliefband had significantly less vomiting episodes overall…

Woodside Biomedical, makers of the ReliefBand(R) Device, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) to market the device without a prescription to pregnant women for relief of mild to moderate nausea and vomiting associated with pregnancy.